

Les données de recherche - *Research data*

R1- Liste des articles originaux publiés en 2008 - *List of original articles published in 2008*

1. Myeloid derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. A.-S. Dugast, T. Haudebourg, F. Coulon, M. Heslan, F. Haspot, N. Poirier, R. Vuillefroy de Sully, C. Usal, H. Smit, B. Martinet, P. Thébaud, K. Renaudin & B. Vanhove. **J Immunol.** 2008, **180** : 7898-7906. [\[IF-2007 \(6.068\)\]](#)
2. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. C. Braud, D. Baeten, M. Giral, A. Pallier, J. Ashton-Chess, C. Braudeau, C. Chevalier, A. Lebars, J. Léger, A. Moreau, E. Pechkova, C. Nicolini, J.-P. Souillou & S. Brouard. **J Cell Biochem.** 2008, **103** : 1681-1692. [\[IF-2007 \(3.381\)\]](#)
3. Lentivirus mediated HO-1 gene transfer enhances myogenic precursor cell survival after autologous transplantation in pig. T. Laumonier, S. Yang, S. König, C. Chauveau, I. Anegon, P. Hoffmeyer & J. Menetrey. **Mol Ther.** 2008, **16** : 404-410. [\[IF-2007 \(5.862\)\]](#)
4. Implication of matrix metalloproteinase 7 and the non-canonical WNT signaling pathway in a model of kidney allograft tolerance induced by the administration of anti-donor class II antibodies. V. Jovanovic, A.-S. Dugast, J. Ashton-Chess, J.-M. Heslan, M. Giral, N. Degauque, A. Moreau, A. Pallier, E. Chiffolleau, D. Lair, C. Usal, H. Smit, B. Vanhove, J.-P. Souillou & S. Brouard. **J Immunol.** 2008, **180** : 1317-1325. [\[IF-2007 \(6.068\)\]](#)
5. Surrogate markers for the prediction of long-term outcome in transplantation: Nantes Actualité Transplantation (NAT) 2007 Meeting Report. S. Brouard, J. Ashton-Chess & J.-P. Souillou. **Hum Immunol.** 2008, **69** : 2-8. [\[IF-2007 \(2.901\)\]](#)
6. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J. Ashton-Chess, M. Giral, M. Mengel, K. Renaudin, Y. Foucher, W. Gwinner, C. Braud, T. Quillard, P. Thébaud, E. Chiffolleau, C. Braudeau, B. Charreau, J.-P. Souillou & S. Brouard. **J Am Soc Nephrol.** 2008, **19** : 1116-1127. [\[IF-2007 \(7.111\)\]](#)
7. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. Sivozhelezov V, Braud C, Giacomelli L, Pechkova E, Giral M, Souillou JP, Brouard S, Nicolini C. **J Cell Biochem.** 2008, **103(6)** : 1693-706. [\[IF-2007 \(3.381\)\]](#)
8. Activity-dependent regulation of tyrosine hydroxylase expression in the enteric nervous system. J. Chevalier, P. Derkinderen, P. Gomes, R. Thinard, P. Naveilhan, P. Vanden Berghe & M. Neunlist. **J Physiol.** 2008, **586** : 1963-1975. [\[IF-2007 \(4.58\)\]](#)
9. Recombinant human C1-inhibits cytotoxicity induced by Allo- and Xenoantibodies. N. Poirier & G. Blanche. **Transpl. Proc.** 2008, **40** : : 581-583. [\[IF-2007 \(1.027\)\]](#)
10. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. L. Berthelot, D.-A. Laplaud, S. Pettré, C. Ballet, L. Michel, S. Hillion, C. Braudeau, F. Connan, F. Lefrère, S. Wiertlewski, J.-G. Guillet, S. Brouard, J. Chopin & J.-P. Souillou. **Eur J Immunol.** 2008, **38** : 1889-1899. [\[IF-2007 \(4.662\)\]](#)
11. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. A. Ouabeb, F.-X. Hubert, D. Chabannes, L. Gautreau, M. Heslan & R. Josien. **J Immunol.** 2008, **180** : 5862-5870. [\[IF-2007 \(6.068\)\]](#)
12. The signaling adaptor protein CD3 is a negative regulator of dendrite development in young neurons. S.J. Baudouin, J. Angibaud, G. Loussouarn, V. Bonnamain, A. Matsuura, M. Kinebuchi, P. Naveilhan & H. Boudin. **Mol Biol Cell.** 2008, **19** : 2444-2456. [\[IF-2007 \(6.028\)\]](#)
13. Contrasted blood and intra-graft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. C. Braudeau, J. Ashton-Chess, M. Giral, E. Dugast, S. Louis, A. Pallier, C. Braud, A. Moreau, K. Renaudin, J.-P. Souillou & S. Brouard. **Transplantation.** 2008, **86** : 130-136. [\[IF-2007 \(3.641\)\]](#)
14. Safety and efficacy of regional intravenous (RI) versus intramuscular (IM) delivery of rAAV1 and rAAV 1 and rAAV 8 to nonhuman primate skeletal muscle. A. Toromanoff, Y. Chérel, M. Guilbaud, M. Penaud-Buldo, R.O'Snyder, M.E. Haskins, J.-Y. Deschamps, L. Guigand, G. Podevin, V.R. Arruda, K.A. High, H.H. Stedman, F. Rolling, I. Anegon, P. Moullier & C. Le Guiner. **Mol Ther.** 2008, **16** : 1291-1299. [\[IF-2007 \(5.862\)\]](#)
15. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. C.B. Drachenberg, J. Odorico, A.J. Demetris, L. Arend, I.M. Bajema, J.A. Bruijn, D. Cantarovich, H.P. Cathro, J. Chapman, K. Dimosthenous, B. Fyfe-Kirschner, L. Gaber, O. Gaber, J. Goldberg, E. Honsova, S.S. Iskandar, D.K. Klassen, B. Nankivell, J.C. Papadimitriou, L.C. Racusen, P. Randhawa, F.P. Reinholt, K. Renaudin, P.P. Revelo, P. Ruiz, J.R. Torrealba, E. Vazquez-Martul, L. Voska, R. Stratta, S.T. Bartlett & D.E.R. Sutherland. **Am J Transplant.** 2008, **8** : :1-13. [\[IF-2007 \(6.423\)\]](#)
16. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. L. Michel, L. Berthelot, S. Pettré, S. Wiertlewski, F. Lefrère, C. Braudeau, S. Brouard, J.-P. Souillou & D.-A. Laplaud. **J Clin Invest.** 2008, **118** : 3411-3419. [\[IF-2007 \(16.915\)\]](#)
17. An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. J.-B. Le Ludeuc, T. Condamine, C. Louvet, P. Thébaud, J.-M. Heslan, M. Heslan, E. Chiffolleau & M.-C. Cuturi. **Am J Transplant.** 2008, **8** : 2297-2306. [\[IF-2007 \(6.423\)\]](#)
18. Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. A. Moreau, E. Chiffolleau, G. Bériou, J.-Y. Deschamps, M. Heslan, J. Ashton-Chess, F. Rolling, R. Josien, P. Moullier, M.-C. Cuturi & B. Alliot-Licht. **Transplantation.** 2008, **85** : : 1351-1356. [\[IF-2007 \(3.641\)\]](#)
19. Chronic lymphocytic leukemia: a hazardous condition before kidney transplantation. d'Ythurbide G, Coppo P, Adem A, Callard P, Dantal J, Chantrel F, Godin M, Braun-Parvez L, Moulin B, Moskovtchenko P, Ouali N, Rondeau E, Hertig A. **Am J Transplant.** 2008, **8** : 2471-5. [\[IF-2007 \(6.423\)\]](#)
20. Nephron mutations can cause childhood-onset steroid-resistant nephrotic syndrome. Philippe Aurélie, Nevo Fabien, Esquivel Ernie L, Reklaityte Dalia, Gribouval Olivier, Tête Marie-Joséphine, Loirat Chantal, Dantal Jacques, Fischbach Michel, Pouteil-Noble Claire, Decramer Stéphane, Hoehne Martin, Benzing Thomas, Charbit Marina, Niaudet Patrick, Antignac Corinne. **J Am Soc Nephrol.** 2008, **19** : 1871-8. [\[IF-2007 \(7.111\)\]](#)
21. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Terrier Benjamin, Jaccard Arnaud, Harousseau Jean-Luc, Delarue Richard, Tournilhac Olivier, Hunault-Berger Mathilde, Hamidou Mohamed, Dantal Jacques, Bernard Marc, Grosbois Bernard, Morel Pierre, Coiteux Valérie, Gisserot Olivier, Rodon Philippe, Hot Arnaud, Elie Caroline, Leblond Véronique, Femand Jean-Paul, Fakhouri Fadi. **Medicine (Baltimore).** 2008, **87** : 99-109.
22. A flexible semi-Markov model for interval-censored data and goodness-of-fit testing. Foucher Yohann, Giral M, Souillou J P, Daures J P. **Stat Methods Med Res.** 2008.
23. Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations. Dailly Eric, Deslandes G, Hourmant M, Petit T, Renaud C, Treilhaud M, Jolliet P. **J Clin Lab Anal.** 2008, **22** : 282-5.
24. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Fakhouri Fadi, Jablonski Mathieu, Lepercq Jacques, Blouin Jacques, Benachi Alexandra, Hourmant Maryvonne, Pirson Yves, Dürrbach Antoine, Grünfeld Jean-Pierre, Knebelmann Bertrand, Frémeaux-Bacchi Véronique. **Blood.** 2008, **112** : 4542-5. [\[IF-2007 \(10.896\)\]](#)

25. Well-differentiated endocrine carcinoma of the renal pelvis: Report of a case with sustained objective response to octreotide. Walter, Thomas;Mege-Lechevallier, Florence;Scoazec, Jean-Yves;Martin, Xavier;Chayvialle, Jean-Alain;Lombard-Bohas, Catherine. **Pathol Res Pract.** 2008
26. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Pasticier, G;Chapet, O;Badet, L;Ardiet, J M;Poissonnier, L;Murat, F J;Martin, X;Gelet, A. **Urology.** 2008 Dec;72(6):1305-9.
27. Radiofrequency ablation of renal tumors with an expandable multitined electrode: results, complications, and pilot evaluation of cooled pyeloperfusion for collecting system protection. Rouvière, Olivier;Badet, Lionel;Murat, François Joseph;Maréchal, Jean Marie;Colombel, Marc;Martin, Xavier; Lyonnet, Denis; Gelet, Albert. **Cardiovasc Intervent Radiol.** 2008 May-Jun;31(3):595-603.
28. Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis. Javouhey, Etienne;Ranchin, Bruno;Lachaux, Alain;Boillot, Olivier;Martin, Xavier;Floret, Daniel;Cochat, Pierre. **Pediatr Transplant.** 2008. *[IF-2007 (1,505)]*
29. Associations among obesity, blood pressure, and left ventricular mass. Maggio, Albane B R;Aggoun, Yacine;Marchand, Laetitia M;Martin, Xavier E;Herrmann, François;Beghetti, Maurice;Farpour-Lambert, Nathalie J. **J Pediatr.** 2008 Apr;152(4):489-93. *[IF-2007 (4.017)]*
30. Kidney transplantation and lower tract obstructive uropathy treated by Botox: a case report. El Fellah, H;Zakaria, Y;Fassi Fehri, H;Badet, L;Martin, X. **Prog Urol.** 2008. Feb;18(2):132-5 *[IF-2007 (0,329)]*
31. Dual kidney transplant: the E. Herriot Hospital Lyon experience. Rognant, N;Codas Duarte, R;De la Torre Abril, L;Fassi Fehri, H;Cuzin, B;Colombel, M;Dawahra, M;McGregor, B;Lefrançois, N;Brunet, M;Daoud, S;Emmanuel, M;Martin, X;Badet, L. **Prog Urol.** 2008 Nov;18(10):678-84. *[IF-2007 (0,329)]*
32. AMS 800 artificial urinary sphincter implantation: can the penoscrotal approach constitute an alternative to the perineal approach? Fassi-Fehri, H;Dinia, E M;Genevoix, S;Murat, F-J;Poissonnier, L;Badet, L;Colombel, M;Martin, X;Gelet, A. **Prog Urol.** 2008 Mar;18(3):177-82. *[IF-2007 (0,329)]*
33. Renal ischemic preconditioning improves recovery of kidney function and decreases alpha-smooth muscle actin expression in a rat model. Timsit, Marc Olivier;Gadet, Rudy;Ben Abdennebi, Hassen;Codas, Ricardo;Petruzzo, Palmina;Badet, Lionel. **J Urol.** 2008. Jul;180(1):388-91. *[IF-2007 (4.053)]*
34. Prostate cancer in renal transplant recipients. Kleinclauss, François;Gigante, Marc;Neuzillet, Yann;Mouzin, Marc;Terrier, Nicolas;Salomon, Laurent;Iborra, François;Petit, Jacques;Cormier, Luc;Lechevallier, Eric. **Nephrol Dial Transplant.** 2008. Jul;23(7):2374-80. *[IF-2007 (3.1)]*
35. Estimation of stature and length of limb segments in children and adolescents from whole-body dual-energy X-ray absorptiometry scans. Abrahamyan, Davit O; Gazarian, Aram; Braillon, Pierre M. **Pediatr Radiol.** 2008. Mar;38(3):311-5. *[IF-2007 (0,991)]*
36. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. Wootla, Bharath;Nicoletti, Antonino;Patey, Natacha;Dimitrov, Jordan D;Legendre, Christophe;Christophe, Olivier D;Friboulet, Alain;Kaveri, Srinivas V;Lacroix-Desmazes, Sébastien;Thaumat, Olivier. **J Immunol.** 2008. Jun 15;180(12):8455-60. *[IF-2007 (6,068)]*
37. B cell survival in intra-graft tertiary lymphoid organs after rituximab therapy. Thaumat, Olivier;Patey, Natacha;Gautreau, Chantal;Lechaton, Sophie;Fremeaux-Bacchi, Véronique;Dieu-Nosjean, Marie-Caroline;Cassuto-Viguié, Elisabeth;Legendre, Christophe;Delahousse, Michel;Lang, Philippe;Michel, Jean-Baptiste;Nicoletti, Antonino. **Transplantation.** 2008. Jun 15;85(11):1648-53. *[IF-2007 (3,641)]*
38. Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Thaumat, Olivier;Louedec, Liliane;Graff-Dubois, Stéphanie;Dai, Jiangping;Groyer, Emilie;Yacoub-Youssef, Houda;Mandet, Chantal;Bruneval, Patrick;Kaveri, Srinivas;Caligiuri, Giuseppina;Germain, Stéphane;Michel, Jean-Baptiste;Nicoletti, Antonino. **Transplantation.** 2008. Jan 27;85(2):281-9 *[IF-2007 (3,641)]*
39. Allogeneic donor bone marrow cells recovery and infusion after allogeneic face transplantation from the same donor. Hequet O, Morelon E, Bourgeot JP, Dubois V, Devauchelle B, Dubernard JM, Michallet M. **Bone Marrow Transplant.** 2008 Jun;41(12):1059-61. *[IF-2007 (3.0)]*
40. Impact of pancreatic venous drainage site on long-term patient and graft outcome in simultaneous pancreas-kidney transplantation. Petruzzo P, Lefrançois N, Berthillot C, Danjou F, Contu P, Codas R, Morelon E, Dubernard JM, Martin X, Badet L. **Clin Transplant.** 2008 Jan-Feb;22(1):107-12. *[IF-2007 (1,5)]*
41. C.SCREENING OF DIABETIC RETINOPATHY: EFFECT OF FIELD NUMBER AND MYDRIASIS ON SENSITIVITY AND SPECIFICITY OF DIGITAL FUNDUS PHOTOGRAPHY. Aptel F, Denis P, Rouberol F, Thivolet. **Diabetes Metab.** 2008 Jun;34(3):290-3. *[IF-2007 (1,74)]*
42. Distinct monocyte gene-expression profiles in autoimmune diabetes. Padmos RC, Schloot NC, Beyan H, Ruwhof C, Staal FJ, de Ridder D, Aanstoot HJ, Lam-Tse WK, de Wit H, de Herder C, Drexhage RC, Menart B, Leslie RD, Drexhage HA; LADA Consortium (C Thivolet as member). **Diabetes.** 2008 Oct;57(10):2768-73. *[IF-2007 (8,261)]*
43. On behalf of the Action LADA Group. Metabolic Syndrome and autoimmune diabetes: ACTION LADA 3. Hawa M, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, Hunter S, Buzzetti R, De Leiva A, Pozzilli P, Leslie RD. **Diabetes Care.** 2008 Oct 22. *[IF-2007 (7,851)]*
44. The international registry on hand and composite tissue transplantation. Petruzzo Palmina, Lanzetta Marco, Dubernard Jean Michel, Margreiter Raimund, Schuind Frédéric, Breidenbach Warren, Noll Robert, Schneeberger Stephan, van Holder Carlo, Kaufman Christina, Jablecki Jerzy, Landin Luis, Cavadas Pedro. **Transplantation.** 2008. 86 : 487-92. *[IF-2007 (3,641)]*
45. Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Richard-Fiardo, Peggy;Payen, Emmanuel;Chèvre, Raphaël;Zuber, Julien;Letrou-Bonneval, Emilie;Beuzard, Yves;Pitard, Bruno. **Hum Gene Ther.** 2008, 19: 331-42. *[IF-2007 (4.33)]*
46. Sirolimus may reduce fertility in male renal transplant recipients. Zuber, J;Anglicheau, D;Elie, C;Bererhi, L;Timsit, M-O;Mamzer-Bruneel, M-F;Ciroidi, M;Martinez, F;Snanoudj, R;Hiesse, C;Kreiss, H;Eustache, F;Laborde, K;Thervet, E;Legendre, C. **Am J Transplant.** 2008, 8: 1471-9. *[IF-2007 (6.423)]*
47. Immune-mediated pure red cell aplasia in renal transplant recipients. Zuber, Julien;Beldjord, Kheira;Casadevall, Nicole;Thervet, Eric;Legendre, Christophe;Varet, Bruno. **Haematologica.** 2008, 93: 1750-2. *[IF-2007 (5.516)]*
48. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Bollée, Guillaume;Anglicheau, Dany;Loup, Alexandre;Zuber, Julien;Patey, Natacha;Mac Gregor, Duncan;Martinez, Frank;Mamzer-Bruneel, Marie-France;Snanoudj, Renaud;Thervet, Eric;Legendre, Christophe;Noël, Laure-Hélène. **Clin J Am Soc Nephrol.** 2008, 3: 1461-8. *[IF-2007 (2.2)]*
49. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Courbebaisse, Marie;Thervet, Eric;Souberbielle, Jean Claude;Zuber, Julien;Eladari, Dominique;Martinez, Frank;Mamzer-Bruneel, Marie-France;Urena, Pablo;Legendre, Christophe;Friedlander, Gerard;Prié, Dominique. **Kidney Int.** 2008 *[IF-2007 (4.9)]*
50. Early conservative intervention for candida contamination of preservative fluid without allograft nephrectomy. Canaud, Guillaume;Timsit, Marc-Olivier;Zuber, Julien;Bougnoux, Marie-Elisabeth;Méjean, Arnaud;Thervet, Eric;Snanoudj, Renaud;Sberro, Rebecca;Martinez, Frank;Legendre, Christophe;Mamzer-Bruneel, Marie-France. **Nephrol Dial Transplant.** 2008, *[IF-2007 (3.167)]*
51. Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function Sberro, Rebecca;Zuber, Julien;Froissart, Marc;Canaud, Guillaume;Prié, Dominique;Martinez, Frank;Mamzer-Bruneel, Marie-France;Anglicheau,

- Dany;Legendre, Christophe;Thervet, Eric. **Transplantation**. 2008;**86**: 558-63. [\[IF-2007 \(3.641\)\]](#)
52. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Anglicheau, D;Loupy, A;Lefaucheur, C;Pessione, F;Létourneau, I;Côté, I;Gaha, K;Noël, L-H;Patey, N;Droz, D;Martinez, F;Zuber, J;Glotz, D;Thervet, E;Legendre, C. **Am J Transplant**. 2008, **8**: 2325-34. [\[IF-2007 \(6.423\)\]](#)
 53. Response of human renal tubular cells to cyclosporine and sirolimus: a toxicogenomic study. Pallet, Nicolas;Rabant, Marion;Xu-Dubois, Yi-Chun;Lecorre, Delphine;Mucchielli, Marie-Hélène;Imbeaud, Sandrine;Agier, Nicolas;Hertig, Alexandre;Thervet, Eric;Legendre, Christophe;Beaune, Philippe;Anglicheau, Dany. **Toxicol Appl Pharmacol**. 2008, **229**: 184-96. [\[IF-2007 \(3.846\)\]](#)
 54. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Anglicheau, Dany;Suthanthiran, Manikkam. **Transplantation**. 2008, **86**: 192-9. [\[IF-2007 \(3.641\)\]](#)
 55. Early epithelial phenotypic changes predict graft fibrosis Hertig, Alexandre;Anglicheau, Dany;Verine, Jérôme;Pallet, Nicolas;Touzot, Maxime;Ancel, Pierre-Yves;Mesnard, Laurent;Brousse, Nicole;Baugey, Edith;Glotz, Denis;Legendre, Christophe;Rondeau, Eric;Xu-Dubois, Yi-Chun. **J Am Soc Nephrol**. 2008, **19**: 1584-91. [\[IF-2007 \(7.111\)\]](#)
 56. Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Pallet, N;Bouvier, N;Bendjallah, A;Rabant, M;Flinois, J P;Hertig, A;Legendre, C;Beaune, P;Thervet, E;Anglicheau, D. **Am J Transplant**. 2008, **8**: 2283-96. [\[IF-2007 \(6.423\)\]](#)
 57. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. Bouvier, Nicolas;Flinois, Jean-Pierre;Gilleron, Jérôme;Sauvage, François-Ludovic;Legendre, Christophe;Beaune, Philippe;Thervet, Eric;Anglicheau, Dany;Pallet, Nicolas. **Am J Physiol Renal Physiol**. 2008, **296**: F160-9. [\[IF-2007 \(4.416\)\]](#)
 58. Autophagy protects renal tubular cells against cyclosporine toxicity. Pallet, Nicolas; Bouvier, Nicolas;Legendre, Christophe;Gilleron, Jerome;Codogno, Patrice;Beaune, Philippe;Thervet, Eric;Anglicheau, Dany. **Autophagy**. 2008, **4**: 783-91. [\[IF-2007 \(4.657\)\]](#)
 59. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjogren's syndrome : correlation with B cell biomarkers and disease activity. Candon S, Gottenberg Je, Bengoufa D, Chatenoud L, Mariette X. **Ann Rheum Dis**. 2008. [\[IF-2007 \(6.411\)\]](#).
 60. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Kared Hassen, Leforban Bertrand, Montandon Ruddy, Renand Amédée, Layseca Espinosa Esther, Chatenoud Lucienne, Rosenstein Yvonne, Schneider Elke, Dy Michel, Zavala Flora. **Blood**. 2008. 112 : 2575-8. [\[IF-2007 \(10.896\)\]](#)
 61. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Béhin Anthony, Mayer Michèle, Kassis-Makhoul Bouchera, Jugie Myriam, Espil-Taris Caroline, Ferrer Xavier, Chatenoud Lucienne, Laforêt Pascal, Eymard Bruno. **Neuromuscul Disord**. 2008. 18 : 443-6. [\[IF-2007 \(2.667\)\]](#)
 62. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. Wynands Jan, Belbouab Reda, Candon Sophie, Talbotec Cécile, Mougenot Jean-François, Chatenoud Lucienne, Schmitz Jacques, Cézard Jean-Pierre, Goulet Olivier, Hugot Jean-Pierre, Ruemmele Frank M. **J Pediatr Gastroenterol Nutr**. 2008. 46 : 293-8. [\[IF-2007 \(2.102\)\]](#)
 63. The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Martinuzzi E, Novelli G, Scotto M, Blancou P, Bach JM, Chaillous L, Bruno G, Chatenoud L, van Enderd P,Mallone R. **Diabetes**. 2008, **57**: 1312-20. [\[IF-2007 \(8.261\)\]](#)
 64. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Durrbach, Antoine;Rostaing, Lionel;Tricot, Leila;Ouali, Nacera;Wolf, Philippe;Pouteil-Noble, Claire;Kessler, Michele;Viron, Beatrice;Thervet, Eric. **Transplantation**. 2008, **85**: 486-90. [\[IF-2007 \(3.641\)\]](#)
 65. Immune-mediated pure red cell aplasia in renal transplant recipients. Zuber, Julien;Beldjord, Kheira;Casadevall, Nicole;Thervet, Eric;Legendre, Christophe;Varet, Bruno. **Haematologica**. 2008
 66. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Courbebaisse, Marie;Thervet, Eric;Soubierbielle, Jean Claude;Zuber, Julien;Eladari, Dominique;Martinez, Frank;Mamzer-Bruneel, Marie-France;Urena, Pablo;Legendre, Christophe;Friedlander, Gerard;Prié, Dominique. **Kidney Int**. 2008
 67. Early conservative intervention for candida contamination of preservative fluid without allograft nephrectomy. Canaud, Guillaume;Timsit, Marc-Olivier;Zuber, Julien;Bougnoux, Marie-Elisabeth;Méjean, Arnaud;Thervet, Eric;Snanoudj, Renaud;Sberro, Rebecca;Martinez, Frank;Legendre, Christophe;Mamzer-Bruneel, Marie-France. **Nephrol Dial Transplant**. 2008
 68. Arteriolar hyalinization predicts delayed graft function in deceased donor renal transplantation. Matignon, Marie;Desvaux, Dominique;Noël, Laure-Hélène;Roudot-Thoraval, Françoise;Thervet, Eric;Audard, Vincent;Dahan, Karine;Lang, Philippe;Grimbert, Philippe. **Transplantation**. 2008, : 1002-5. [\[IF-2007 \(3.641\)\]](#)
 69. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment : a two-year follow-up in kidney transplantation. S. Sanquer, P. Maison, C. Tomkiewicz, I. Macquin-Mavier, Ch. Legendre, R. Barouki, P. Lang. **Clinical Pharmacology and Therapeutics** 2008 ; **83**: 32 [\[IF-2007 \(8.033\)\]](#)
 70. Improving outcomes for solid organ transplant recipients at risk from cytomegalovirus infection (CMV) : late-onset disease and indirect consequences. Ch. Legendre, M. Pascual. **Clinical Infectious Diseases**. 2008 : **46**: 732-40. [\[IF-2007 \(6.750\)\]](#)
 71. Letter : Reply to Singh. Ch. Legendre, M. Pascual. **Clinical Infectious Diseases** 2008 : **47** :297-8.
 72. Intravenous immunoglobulins-induced macrovacuoles promote chronic tubulointerstitial lesions in renal transplant recipients. G. Bollée, D. Anglicheau, A. Loupy, J. Zuber, N. Patey, F. Martinez, M-F. Mamzer-Bruneel, R. Snanoudj, E. Thervet, Ch. Legendre, L-H. Noël. **Clinical Journal of the American Society of Nephrology** 2008 ; **3**:1461-8. [\[IF-2007 \(7.111\)\]](#)
 73. Early epithelial phenotypic changes predict graft fibrosis. A. Hertig , D. Anglicheau, J. Vérine , N. Pallet , M. Touzot M, PY. Ancel , L. Mesnard L, N. Brousse , E. Beaugey , D. Glotz , Ch. Legendre , E. Rondeau , Y.C. Xu-Dubois . **J Am Soc Nephrol** 2008 ; **19** : 1584-91. [\[IF-2007 \(7.111\)\]](#)
 74. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. M. Le Quintrec, A. Lionet, N. Kamar, A. Karras, S. Barbier, M. Buchler, F. Fakhouri, F. Provost, W-H. Fridman, E. Thervet, Ch. Legendre, J. Zuber, V. Frémeaux-Bacchi. **AmJ Transplant** 2008 ; **8** : 1674-701. [\[IF-2007 \(6.423\)\]](#)
 75. Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. N. Pallet, N. Bouvier, A. Bendjallah , M. Rabant, J.P. Flinois, A. Hertig, S. Imbeaud, E. Thervet, Ch. Legendre, P. Beaune, D. Anglicheau . **Am J Transplant** 2008 ; **8** : 2283-96. [\[IF-2007 \(6.423\)\]](#)
 76. Less pessimistic long-term results for patients with cytomegalovirus disease. A. Scemla, H. Kreis, Ch. Legendre. **Clinical Infectious Diseases**. 2008 ; **47** : 1360-1; author reply 1361-2 [\[IF-2007\(6.750\)\]](#)
 77. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplant recipients. B. Wootla, A. Nicoletti, N. patey, J.D. Dimitrov, Ch. Legendre, O.D. Christophe, A. Friboulet, S. V. Kaveri, S. Lacroix-Desmazes, O. Thauinat. **Journal of Immunology** 2008 ; **180** : 8455-60. [\[IF-2007 \(6.068\)\]](#)

R2- Liste des revues et éditoriaux - *List of reviews and editorials*

1. Peut-on prédire une tolérance aux allogreffes ? J.P. Souillou, M. Giral, C. Braud & S. Brouard. **Necker Seminar in Nephrology**. 2008. *[IF-2006 (0)]*
 2. Spontaneous operational tolerance following immunosuppressive drug withdrawal in clinical renal allotransplantation. J. Ashton-Chess, M. Giral, S. Brouard & J.-P. Souillou. **Transplantation**. 2008, 84 : 1215-1219. *[IF-2007 (3.641)]*
 3. Immunosuppression minimization in kidney transplantation. D. Cantarovich, F. Vistoli & J.-P. Souillou. **Front Biosci**. 2008, 13 : 1413-1432. *[IF-2006 (2.771)]*
 4. Anti-interleukin 2 receptor. B. Le Mauff & J.-P. Souillou. **International Transplantation Updates - New Uses of Biological Agents in Organ Transplantation**. 2008. 47-65.
 5. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. J.M. Campistol, J. Albanell, W. Arns, I. Boletis, J. Dantal, J.W. de Fijter, S.A. Mortensen, H.H. Neumayer, O. Oyen, J. Pascual, E. Pohanka, F.P. Schena, D. Seron, V. Sparacino & J.R. Chapman. **Nephrol Dial Transpl**. 2008, 22 : 36-41. *[IF-2007 (3.167)]*
 6. Transfer of tolerance to heart and kidney allografts in the rat model. V. Jovanovic, D. Lair, J.-P. Souillou & S. Brouard. **Transpl Int**. 2008, 21 : 199-206. *[IF-2007 (2.3)]*
 7. mTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature. Y. Neuzillet, G. Karam, E. Lechevallier, F. Kleinclauss & Comité de Transplantation de l'Association Française d'Urologie. **Prog Urol**. 2008, 17 : 928-933. *[IF-2007 (0.329)]*
 8. Dendritic cells as killers: mechanistic aspects and potential roles. C. Chauvin & R. Josien. **J Immunol**. 2008, 181 : 11-16. *[IF-2007 (6.068)]*
 9. Aspects immunologiques des infections virales. G. Blancho. **Le Courrier de la Transplantation**. 2008, **numéro spécial**: 12-15.
 10. Face transplantation. Dubernard Jean-Michel, Devauchelle Bernard. **Lancet**. 2008. 372 : 603-4
 11. Lymphoid neogenesis in chronic rejection. O. Thauinat, A. Nicoletti. **Curr Opin Organ Transplant**. 2008 Feb; 13 (1) : 16-9. Review.
 12. Atherogenesis: a dysimmune disease. A Varthaman, J Khalou-Laschet, O Thauinat, G Caligiuri, A Nicoletti. **Med Sci (Paris)**. 2008 Feb; 24(2):169-75. Review. French
 13. Comment on « Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren' syndrome » O Thauinat, A Nicoletti. **J Immunol**. 2008 Feb 15; 180(4):2007-8: author reply 2008-9.
 14. Can immune monitoring help to minimize immunosuppression in kidney transplantation? Ashton-Chess Joanna, Giral Magali, Souillou Jean-Paul, Brouard Sophie. **Transpl Int**. 2008.
 15. Anti-human leukocyte antigen antibodies after islet transplantation: what do they really mean?. Cantarovich Diego, Vistoli Fabio, Bignon Jean-Denis. **Transplantation**. 2008. **86** : 204-5.
 16. When to place a patient on the kidney transplantation waiting list?. Kessler Michèle, Büchler Mathias, Durand Dominique, Kolko-Labadens Anne, Lefrançois Gaele, Menoyo Victorio, Mourad Georges, Peraldi Marie-Noelle, Pouteil-Noble Claire, Yver Laurent, Zins Brigitte, Hourmant Maryvonne, **Nephrol Ther**. 2008. **4** : 155-9.
 17. Selection of the living donor. Hourmant Maryvonne. **Nephrol Ther**. 2008. **4** : 63-6.
 18. Living-donor kidney transplantation in children. Cochat, Pierre;Badet, Lionel. **Nephrol Ther**. 2008
 19. Lymphoid neogenesis in chronic rejection. Thauinat, Olivier;Nicoletti, Antonino. **Curr Opin Organ Transplant**. 2008
 20. Lymphoid neogenesis and lymphangiogenesis: Two newcomers in the pathophysiology of chronic rejection.. Attuill-Audenis, Valérie;Duthey, Aurélie;Patey, Natacha;Gautreau, Chantal;McGregor, Brigitte;Morelon, Emmanuel;Michel, Jean-Baptiste;Nicoletti, Antonino;Thauinat, Olivier. **Nephrol Ther**. 2008
 21. Atherogenesis: a dysimmune disease. Varthaman, Aditi;Khalou-Laschet, Jamila;Thauinat, Olivier;Caligiuri, Giuseppina;Nicoletti, Antonino. **Med Sci (Paris)**. 2008
 22. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Sarti C, Thivolet C, Hadden D, Hunter S, Scherthner G, Scherbaum W, Williams R, Pozzilli P. **Diabetes Metab Res Rev**. 2008 Oct;24(7):511-9
 23. What's new in immunological monitoring? Zuber, J. **Nephrol Ther**. 2008, 4 Suppl 1: S3-S7.
 24. Nephropathy and autoimmune enteropathies: role of CD4+CD25+FOXP3+ T cell regulatory functions. Zuber, Julien. **Nephrol Ther**. 2008, 4: 43-4.
 25. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Thervet, Eric; Anglicheau, Dany; Legendre, Christophe; Beaune, Philippe. **Ther Drug Monit**. 2008, 30: 143-50.
 26. The long and winding road towards induction of allograft tolerance in the clinic. Chatenoud Lucienne. **Transpl Int**. 2008. 21 : 725-7. *[IF-2007 (2.300)]*
 27. Chemical immunosuppression in islet transplantation--friend or foe?. Chatenoud Lucienne. **N Engl J Med**. 2008. 358 : 1192-3. *[IF-2007 (52.589)]*
 28. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. You S, Candon S, Kuhn C, Bach JF, Chatenoud L. **Adv Immunol**. 2008, 100: 13-37.
 29. Toward cell-based therapy of type I diabetes. Kabelitz Dieter, Geissler Edward K, Soria Bernat, Schroeder Insa S, Fändrich Fred, Chatenoud Lucienne. **Trends Immunol**. 2008. 29 : 68-74. *[IF-2007 (9.480)]*
 30. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic. Chatenoud L. **Handb Exp Pharmacol**. 2008. : 221-36.
 31. Recents advances in the pharmacology of immunosuppressive drugs. Thervet, Eric. **Med Sci (Paris)**. 2008
 32. Individualization of nursing of patients after transplantation. Thervet, Eric. **Soins**. 2008
 33. Screening biopsies in kidney transplantation: from subclinical acute rejection to chronic allograft lesions. Snanoudj R, Martinez F, Sberro Soussan R, Thervet E, Legendre C. **Nephrol Ther**. 2008
 34. mTor inhibitors-induced proteinuria : mechanisms, significance and management. E. Letavernier, Ch. Legendre. **Transplantation Reviews** 2008 ;22 :125-30.).
 35. Determination of the « best predictable creatinine » in renal transplant recipients using donor's characteristics. R. Sberro, J. Zuber, M. Froissart, G. Canaud, D. Prié, F. Martinez, M.F. Mamzer-Bruneel, Ch. Legendre, E. Thervet. **Transplantation** 2008 ;86 : 558-63. *[IF-2007 (3.641)]*
 36. Kaposi's sarcoma in transplantation. C. Lebbé, Ch. Legendre, C. Francès. **Transplantation Reviews** 2008 ; 22 : 252-61.
- Autres - Others*
37. Préface. J.-P. Souillou. Médecine translationnelle : les fondamentaux en pharmacologie et les traitements immunosuppresseurs. Coordination : Pr. Eric Thervet, **Le Praticien, Da Te Be Editions**. 2008. 7-8. *[IF-2006 (0)]*
 38. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. X.-L. Li, S. Ménoret, B. Le Mauff, M. Angin & I. Anegon. **Transplantation**. 2008, 86 : 10-15. *[IF-2007 (3.641)]*

39. Progress and prospects: genetic engineering in xenotransplantation. S. Le Bas-Bernardet, I. Anegon & G. Blancho. **Gene Ther.** 2008, 15 : 1247-1256. *[IF-2007 (4.812)]*
40. Pathological lesions in colonic biopsies during Parkinson's disease. T. Lebouvier, T. Chaumette, P. Damier, E. Coron, Y. Touchefeu, S. Vrignaud, P. Naveilhan & J.-P. Galmiche. **Gut Month.** 2008. *[IF-2007 (10)]*

R3- Liste des communications orales et posters, ouvrages et proceedings - *List of oral communications, posters, works and proceedings*

Communications orales - oral communications

1. Activation of the Notch pathway in vascular endothelial cells prevents apoptosis by promoting protective gene expression and survival pathway: implication in transplant arteriosclerosis. T.Quillard, S. Coupel, F.Coulon, J. Fitau, M.C Cuturi, E.Chiffolleau and B.Charreau. **American Transplant Congress 2008**, Toronto, Canada, May 31 - June 4, 2008.
2. Inhibition of Notch4 Expression and Notch Activity in EC Promotes Apoptosis and Correlates with Transplant Arteriosclerosis. T.Quillard, S.Coupel, F.Coulon, J.Fitau, M.C Cuturi, E.Chiffolleau and B.Charreau. **International Vascular Biology Meeting**, Sydney, Australia, June 1-5 2008.
3. Immunomodulation induced by a CD28 antagonist in kidney allograft baboon recipients. N. Poirier, C. Mary, E. Allain-Launay, T. Haudebourg, K. Renaudin, X. Tillou, S. Le Bas-Bernardet, N. Dilek, G. Karam, F. Vistoli, B. Vanhove and G. Blancho. **Nantes Actualités Transplantation**, Nantes, France, June 26-27, 2008.
4. Immunomodulation induced by a CD28 antagonist in kidney allograft baboon recipients. N. Poirier, C. Mary, E. Allain-Launay, T. Haudebourg, K. Renaudin, X. Tillou, S. Le Bas-Bernardet, N. Dilek, G. Karam, F. Vistoli, B. Vanhove and G. Blancho. **XXII International Congress of the Transplantation Society**, Sydney, Australia, August 10-14, 2008.
5. Mise au point d'un crossmatch endothélial spécifique du donneur : étude pilote sur une cohorte de 22 transplantations rénales. E.Canet ; S. Le Bas-Bernardet; M.Giral; JP.Souillou; B.Charreau; S.Coupel. **10ème Réunion Commune Société de Néphrologie/SFD**, Marrakech, Morocco, November 26-29 th 2008.
6. Prévention du rejet vasculaire aigu à médiation humorale chez le babouin alloimmunisé par du C1 inhibiteur recombinant humain. X.Tillou, N.Poirier, et al. **8ième Congrès de la Société Francophone de Transplantation (SFT)**, Québec, Canada, 2008.
7. Immunomodulation en allotransplantation rénale chez le primate non-humain induite par un antagoniste de CD28. N.Poirier, et al. **8ième Congrès de la Société Francophone de Transplantation (SFT)**, Québec, Canada, 2008.
8. Immunomodulation induced by a CD28 antagonist in kidney baboon recipient. N.Poirier, et al. **XXII international congress of the transplant society**, Sydney, Australia, 2008.
9. CD28 antagonist induce immunomodulation in kidney allograft in non-human primate. N.Poirier, et al. **14ième N.A.T (Nantes/actualités/Transplantation)**, Nantes, France, 2008.
10. Pediatric renal transplantation: report from a French pediatric database. E.Allain-Launay, G.Roussey-Kesler, G.Guest, B.Ranchin, A.Maisin, J.Andre, S.Cloarec, Y.Foucher, C.Guyot. **European Society for Paediatric Nephrology**, 2008.
11. An adaptation of time-dependent ROC curves to construct a prognosis test based on the repetition of a surrogate marker: Application on the kidney graft failure and the creatinine clearance. Y.Foucher, M.Giral, JP.Souillou, JP Daurès. **International Society for Clinical Biostatistics**, Copenhagen, Denmark, 2008.
12. New tool to analyse confounding factors in kidney graft outcome: a DIVAT data base stud. M.Giral, Foucher Y, Daurès J.P, Souillou J.P. **American Transplant Congress (ATC)**, Toronto, Canada, 2008.
13. The immunoproteasome subunit beta 10 as a novel peripheral blood and intragraft biomarker of chronic antibody mediated allograft rejection in clinical transplantation. J.Asthon-chess, V.Jovanovic, Y.Foucher, E.Dugast, M.Giral, K.Renaudin, M.Heslan, J.P Souillou, S.Brouard. **American Transplant Congress**. Toronto, Canada, 2008.
14. Avantage des cellules souches mésenchymateuses pour la transplantation neurale. X. Levêque, V Nerrière-Daguin, R. Thynard, L. Lescaudron, I. Neveu et P. Naveilhan. **1^{er} Colloque POLEN**, Nantes, France.
15. Création d'un nouveau modèle de rat transgénique parkinsonien dans le but de développer de nouvelles thérapies. C. Boyer, R. Thinar, S. Rémy, C. Usal, L. Tesson, I. Anegon, P. Damier, P. Naveilhan et L. Lescaudron. **1^{er} Colloque POLEN**, Nantes, France.
16. Mesenchymal stem cell and adult neural stem cell transplantations in the striatum of a transgenic rat model of Huntington's disease. J. Rossignol, J.C. Boyer, J. Matchynski, S. Lowrance, M. Lu, K. Raber, N.Dey, S. von Hörsten, G.L. Dunbar and L. Lescaudron. **Society for Neuroscience Meeting**, Washington, U.S.A.
17. The alpha-synuclein rat: A new transgenic model of presymptomatic Parkinson's disease. C. Boyer, R. Thinar, S. Rémy, C. Usal, L. Tesson, I. Anegon, P. Damier, P. Naveilhan and L. Lescaudron. **Society for Neuroscience Meeting**, Washington, U.S.A.
18. Diabète 2 : des mesures hygiéno-diététiques à l'insuline. C Thivolet. **Rencontres diabétologie Novo-Nordisk 2008**, Lyon, France, November 15-16 2008,
19. Nouveaux outils de mesure de la glycation en clinique. C Thivolet. **Symposium régional GSK**. Grenoble, France October 10 2008.
20. Diabète du sujet âgé. C Thivolet. **Réunion SANOFI**. Lyon, France, September 30 2008.
21. Recommandations thérapeutiques dans le diabète 2 : place des incrétines. C Thivolet. **Réunion Lilly**. Lyon, France, September 12 2008.
22. Remplacement des cellules bêta : Quelles cellules ? Quels diabètes ? C Thivolet. **Réunion endocrinologique de Cochîn**, Paris, France, May 2008.
23. Place des modèles expérimentaux dans les essais d'immunointervention du diabète de type 1.C. Thivolet. **Congrès de l'ALFEDIAM**. Brussels, Belgium, March 2008.
24. Les cellules souches mésenchymateuses (CSM) préviennent le diabète autoimmun de la souris NOD en générant des lymphocytes T régulateurs. A-M Madec, E Abou Mrad, R Mallone, G Afonso, C Thivolet. **ALFEDIAM 2008**.
25. Mesenchymal Stem Cells Protect NOD Mice from Diabetes by Inducing Regulatory T Cells. AM Madec, R. Mallone, G. Afonso, E. Abou MRad, A. Mesnier, A. ElJaafari, C. Thivolet. **EASD ROME 2008**. Rome, Italy.
26. Effets du blocage du récepteur AT1 sur la fonction des îlots pancréatiques humain. S.Dubois, A.M Madec, A. Mesnier, M. Armanet, R. Baertschiger, T. Berney, C. Thivolet. **ALFEDIAM Strasbourg 2009**.
27. Néogenèse lymphoïde au cours du rejet chronique: détournement d'un programme biologique embryonnaire afin d'établir une réponse alloimmune humorale dans le greffon. O Thauat, N Patey, C Gautreau, E Morelon, JB Michel, A Nicoletti. **Société Francophone de Transplantation**, Québec, Canada, October 2008.
28. La correction de l'anémie améliore la qualité de vie des patients transplantés rénaux : résultats de l'étude CAPRIT. G. Choukroun, L. Rostaing, B. Dussol, I. Etienne, E. Cassuto-Viguer, O. Toupance, C. Noel, B. Hurault de Ligny, B. Moulin, Y. Lebranchu, G. Touchard, F. Martinez (Amiens, Toulouse, Marseille, Rouen, Nice, Reims, Lille, Caen, Strasbourg, Tours, Poitiers, Paris). 2008
29. L'incidence de la reprise retardée de fonction après transplantation rénale n'est pas affectée par l'introduction de novo d'évérolimus: résultats de l'étude. Callisto,

- multicentrique, randomisée, comparant introduction immédiate versus retardée d'évérolimus. E. Cassuto, L. Rostaing, F. Berthoux, M.C. Moal, C. Legendre, F. Di Giambattista, J. Dantal (Nice, Toulouse, Saint-Etienne, Brest, Paris, Rueil-Malmaison, Nantes). **Congrès de la Société de Néphrologie** 2008
30. Sirolimus-induced infertility in male renal transplant recipients. Zuber J, Anglicheau D, Bererhi L, Elie C, Ciroidi M, Mamzer-Bruneel MF, Martinez F, Thervet E, Legendre C. **American Transplant Congress (ATC)**, Toronto, Canada, 2008.
 31. A simple composite clinical and histological score is highly predictive of graft outcome in marginal donors (MD). Anglicheau D, Loupy A, Pessione F, Noel LH, Patey N, Droz D, Martinez F, Thervet E, Legendre C. **American Transplant Congress (ATC)**, Toronto, Canada, 2008.
 32. Columbia classification of Focal and Segmental Glomerulosclerosis (FSGS) and the risk of recurrence after transplantation. Canaud G, Noel LH, Dion D, Zuber J, Sberro R, Snanoudj R, Thervet E, Mamzer MF, Martinez F, Legendre C. **American Transplant Congress (ATC)**, Toronto, Canada, 2008
 33. Comparison at one year of interstitial fibrosis (IF) by automate quantification in renal transplant recipients with cyclosporine (CSA) discontinuation and Sirolimus (SRL) introduction. Servais A, Meas-Yedid V, Lebranchu Y, Etienne I, Touchard G, Legendre C, Westeel PF, Toupance O, Hurrault de Ligny B, Olivo-Marin C, Thervet E. **American Transplant Congress (ATC)**, Toronto, Canada, 2008
 34. A prospective randomized study of pharmacogenetic adaptation of tacrolimus treatment after renal transplantation. Thervet E, Lorient MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Alberti C, Legendre C, Beaune P. **American Transplant Congress (ATC)**, Toronto, Canada, 2008
 35. Similar results of single and dual Transplantations with expanded criteria donor kidneys allocated according to donor's estimated glomerular filtration rate. Snanoudj R, Timsit MO, Tricot L, Loupy A, Zuber J, Kreis H, Martinez F, Thervet E, Mejean A, Lebre T, Legendre C, Delahousse M. **American Transplant Congress (ATC)**, Toronto, Canada, 2008
 36. Rôle des macrovacuoles induites par les immunoglobulines intraveineuses dans la progression des lésions tubulo-interstitielles chroniques chez le transplanté rénal. G. Bollée, D. Anglicheau, A. Loupy, J. Zuber, N. Patey, D. Mac Gregor, F. Martinez, M.F. Mamzer-Bruneel, R. Snanoudj, E. Thervet, C. Legendre, L.H. Noel (Paris). **Congrès de la Société de Néphrologie** 2008
 37. Mécanismes immunologiques de l'effet tolérogène de l'anticorps anti-CD3. A. Sartorius, J. Zuber, S. You, E. Thervet, C. Legendre, L. Chatenoud (Paris). **Congrès de la Société de Néphrologie** 2008
 38. Etude prospective randomisée d'adaptation pharmacogénétique d'un traitement par tacrolimus (TAC) en transplantation rénale. E. Thervet, M.A. Lorient, S. Barbier, M. Buchler, M. Ficheux, G. Choukroun, C. Alberti, C. Legendre, P. Beaune **Congrès de la Société de Néphrologie** (Paris, Rouen, Tours, Caen, Amiens).
 39. L'érythropoïétine humaine recombinante protège de la néphrotoxicité de la ciclosporine. N. Pallet, N. Bouvier, P. Beaune, C. Legendre, D. Anglicheau, F. Martinez (Paris). **Congrès de la Société de Néphrologie** 2008
 40. Prévalence de l'infection à Parvovirus 4 chez le malade hémodialysé. C. Legendre. **Congrès de la Société de Néphrologie** 2008
 41. Variantes histologiques de la hyalinose segmentaire et focale et risque de récurrence après transplantation rénale. G. Canaud, D. Dion, J. Zuber, L.H. Noel, K. Gaha, R. Sberro, E. Thervet, R. Snanoudj, C. Legendre, F. Martinez (Paris) **Congrès de la société de Nephrologie** 2008
 42. Atelier éthique : la loyauté dans la pratique médicale. C. Legendre. 2008
 43. Modérateurs: Catherine Dupre-Goudable (Toulouse), Abderrahim Idrissi Kaïtouni (Marrakech)
 - Approche philosophique : la loyauté, vertu et valeur éthique. Bensalem Himmich (Rabat)
 - Le juge, l'éthique, la loyauté : la genèse d'une alchimie. Fabienne Clement-Neyrand (Bordeaux)
 - L'exemple de l'information et du consentement en transplantation : de l'inscription sur la liste d'attente à la participation à une recherche. Marie-France Mamzer (Paris) 2008.
 44. The risk of wound healing complications is comparable in patients treated by everolimus versus MPA in the early phase after kidney transplantation. C. Legendre, M-C. Moal, E. Cassuto, L. Rostaing, F. Berthoux, F. di Giambattista, J. Dantal. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 45. Prospective evaluation of the risk benefit ratio of a vitamin D treatment during the early period after renal transplantation. E. Thervet, M. Courbebaisse, J. Claude Couberbielle, J. Zuber, F. Martinez, M. F. Mamzer, C. Legendre, G. Friedlander, D. Prié. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 46. No exclusion of HHV-8 infected donors and recipients for kidney transplantation: a French prospective national cohort. C. Frances, A-G. Marcelin, C. Legendre, S. Chevret, E. Dussaix, J. Lejeune, A. Bigorie, T. Schulz, F. Agbalika, C. Lebbe. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 47. Preliminary two-year efficacy results from a randomized, open-label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + Mycophenolate regimen (MMF) in de novo renal allograft recipients. S.M. Flechner, S. Cockfi eld, J. Grinyo, G. Russ, K.M. Wissing, C. Legendre, J.B. Copley, for the ORION Trial Investigators. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 48. The incidence of delayed graft function (DGF) following kidney transplantation is not affected by de novo everolimus therapy. C. Legendre, E. Cassuto, L. Rostaing, F. Berthoux, M.C. Moal, F. di Giambattista, J. Dantal. **XIII International Congress of the Transplantation Society**, Sidney, Australia August 2008.
 49. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction. E. Thervet, A. Servais, V. Meas-Yedid, Y. Lebranchu, I. Etienne, G. Touchard, C. Legendre, P.F. Westeel, C. Olivo-Marin. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 50. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2-year safety results from the ORION trial. S. Flechner, S. Cockfi eld, J. Grinyo, G. Russ, K.M. Wissing, C. Legendre, J.B. Copley, for the ORION Trial Investigators. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.

Posters

1. Rôle de la protéine adaptatrice Lnk dans la voie des intégrines et dans le contrôle des adhésions focales et de la migration cellulaire. J. Devallière, J. Fitau, M. Chatelais, F. Coulon et B. Charreau. **11^e Colloque des cytokines**. Le Croisic, France, May 5-7 2008.
2. Long-term survival of porcine neural precursor cells in the rat brain: characterization of their immunoregulatory properties. V. Bonnamain, D. Michel, V. Nerrière-Daguin, R. Thinar, A.S Dugast, P. Brachet, I. Anegon, B. Vanhove, I. Neveu, P. Naveilhan. **Forum Européen des Neurosciences FENS**, July 12-16 2008.
3. Constitutive expression of TRANCE (TNF-related activation-induced cytokine) in rat plasmacytoid dendritic cells. T. Anjubault, C. Chauvin, L. Gautreau-Rolland, D. Chabannes, F.X Hubert and R.Josien. **Congrès DC**, Kobe, Japon. October 1-5 2008.
4. Immunoregulatory properties of neural precursor cells: in vitro characterization. V. Bonnamain, D. Michel, V. Nerrière-Daguin, R. Thinar, A.S Dugast, P. Brachet, I. Anegon, B. Vanhove, I. Neveu, P. Naveilhan. **9th International Neuroimmunology Congress** - Fort Worth, Texas, USA, October 26-30 2008.
5. Expression basale et régulée de la molécule de CMH-I non classique MICA : impact fonction et voies de signalisation impliquées. A. Chauveau, M. Chatelais, B. Charreau et S. Coupel. **10ème Réunion Commune Société de Néphrologie/SFD**, Marrakech, Morocco, November 26-29 2008.

6. NFκB-dependent inhibition of endothelial Notch4 expression and decrease in Notch activity are hallmarks of Transplant Arteriosclerosis and allograft Chronic Rejection. T. Quillard, S. Coupel, F. Coulon, J. Fitau, M.C Cuturi, E. Chiffolleau and B. Charreau. **American transplant Congress (ATC)**, Toronto, Canada 2008.
 7. Immunomodulation in non-human primate kidney allotransplantation after therapy with antagonist monovalent anti-CD28 antibodies. N. Poirier, et al. **American Transplant Congress (ATC)**, Toronto, Canada 2008.
 8. Immunomodulation en allotransplantation rénale chez le primate non-humain induite par un antagoniste de CD28, N.Poirier, et al., **Forum des doctorants**, Nantes, France 2008.
 9. Courbes Roc Multi-états et temps dépendantes. Y. Foucher, J.P Souillou., M. Giral. **Biostatistique et mesures subjectives en santé**. Nantes, France 2008.
 10. Chaines de Markov non homogènes d'ordre 1 à temps discrets à l'étude de l'observance de patients toxicomanes substitués au Subutex. M. Huet, Y. Foucher, M. Guillou-Landreat, C. Vitorri-Vigneau, P. Jolliet, V. Sébille. **Biostatistique et mesures subjectives en santé**, Nantes, France 2008.
 11. Intraatrial transplantation of bone marrow stem cells that are genetically engineered to overexpress brain derived neurotrophic factor reduces behavioral deficits in the yeast artificial chromosome mouse model of Huntington's disease. MC Bombard, ND. Dey, BP. Roland, M. Lu, J. Matchynski, S. Lowrance, J. Rossignol, M I. Sandstrom, L. Lescaudron, and G L. Dunbar. **15th American Society for Neural Therapy and Repair Conference (ASNTR)**, Clearwater Beach, Florida, U.S.A. May 2008
 12. Le rat alpha-synucléine, un modèle pré-clinique de la maladie de Parkinson. C. Boyer, R. Thinard, S. Rémy, C. Usal, L. Tesson, I. Anegon, P. Damier, P. Naveilhan et L. Lescaudron. **Forum des Doctorants**. Ecole Doctorale Chimie-Biologie, Université de Nantes, France 2008.
 13. A new transgenic model of Parkinson's disease: the alpha-synuclein rat. C. Boyer, R. Thinard, S. Rémy, C. Usal, L. Tesson, I. Anegon, P. Damier, P. Naveilhan et L. Lescaudron. **6th FENS Meeting**, Genève, Switzerland, 2008.
 14. Treatment of Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease using a Dietary Supplement that is rich in Anti-oxidants and Omega 3, 6, and 9 Fatty Acids. MC. Bombard, ND. Dey, S. Lowrance, J. Matchynski, J. Rossignol, M. Lu, M. S. Sandstrom, L. Lescaudron and GL. Dunbar. **MISFN Annual Meeting**, Detroit, U.S.A, 2008.
 15. Use of a Dietary Supplement Rich in Anti-oxidants and Omega Fatty Acid 3, 6, and 9 to Reduce Behavioral Deficits in the R6/2 Transgenic Mouse Model of Huntington's Disease. MC. Bombard, ND. Dey, S. Lowrance, J. Matchynski, J. Rossignol, M. Lu, S. Sandstrom, L. Lescaudron and GL. Dunbar. **Society for Neuroscience Meeting**, Washington, U.S.A, 2008.
 16. Inflammatory microenvironment rescues B-cells of tertiary lymphoid organs from rituximab therapy. O. Thauinat, N. Patey, C. Gautreau and A. Nicoletti. **American Transplant Congress** (Toronto). mai 2008.
 17. IgG-mediated hydrolysis of coagulation factors is associated with a reduced risk for chronic allograft nephropathy. O. Thauinat, B. Wootla, N Patey, C. Legendre, A. Nicoletti, S. Lacroix-Desmazes. **American Transplant Congress**, Toronto, Canada, May 2008.
 18. L'autophagie est un mécanisme protecteur contre la toxicité tubulaire de la ciclosporine. N. Pallet, N. Bouvier, C. Legendre, P. Beaune, E. Thervet, D. Anglicheau. 2008.
 19. Effets néphroprotecteurs du blocage du stress du réticulum endoplasmique. N. Pallet, N. Bouvier, C. Legendre, P. Beaune, E. Thervet, D. Anglicheau. 2008.
 20. Traitement intensif des récidives de hyalinose segmentaire et focale: résultats d'une étude pilote menée à Necker. G. Canaud, J. Zuber, F. Martinez, R. Sberro, R. Snanouj, E. Thervet, LH. Noel, C. Legendre. 2008.
 21. La ciclosporine, contrairement au tacrolimus, induit une transition endothélio-mésenchymateuse. N. Bouvier, E. Thervet, C. Legendre, P. Beaune, D. Anglicheau, N. Pallet. 2008.
 22. Effet aigu du traitement par cinacalcet sur la calciurie chez des patients transplantés rénaux (TR). M. Courbebaisse, M. Le Quintrec, J. Zuber, D. Eladari, MF. Mamzer, E. Thervet, C. Legendre, G. Friedlander, F. Martinez, D. Prié. Toronto, Canada, May 31 2008.
 23. Etude cas-contrôle d'un traitement par vitamine D3 sur le bilan phosphocalcique en période précoce après transplantation rénale. M. Courbebaisse, E. Thervet, JC. Souberbielle, J. Zuber, D. Eladari, F. Martinez, MF. Mamzer, P. Urena, C. Legendre, G. Friedlander, D. Prié. 2008.
 24. Le risque de complications de la cicatrisation est identique chez les patients traités par Everolimus ou par MPA dans la période précoce post-transplantation rénale. MC. Moal, L. Albano, F. Berthoux, N. Kamar, C. Legendre, AS. Blanc, F. Di Giambattista, J. Dantal. 2008.
 25. Apoptose endothéliale en situation d'hypoxie +/- ré-oxygénation : application sur des biopsies de préparation de greffons rénaux. T. Dolley Hitze, F. Jouan, B. Martin, D. Gilot, C. Legendre, R. Primault, N. Rioux Leclerc, C. Vigneau. 2008.
 26. IGG-Mediated hydrolysis of coagulation factors is associated with a reduced risk of chronic allograft nephropathy in renal transplanted patients. O. Thauinat, B. Wootla, C. Legendre, A. Nicoletti, S. Lacroix-Desmazes. **XIII International Congress of the Transplantation Society**, Sidney, Australia August 2008.
 27. Prospective randomized study of pharmacogenetic adaptation of tacrolimus treatment after renal transplantation. E. Thervet, M.A. Lorient, S. Barbier, M. Buchler, B. Hurault de Ligny, G. Choukroun, C. Legendre, C. Alberti, P. Beaune. **XIII International Congress of the Transplantation Society**, Sidney, Australia, August 2008.
 28. Cardiovascular risk profile of renal transplant recipients enrolled in an open label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC) + mycophenolate regimen (MMF): preliminary results from the ORION trial. G. Russ, S.M. Flechner, S. Cockfield, J. Grinyo, K.M. Wissing, C. Legendre, J.B. Copley, for the ORION Trial Investigators. **XIII International Congress of the Transplantation Society**, Sidney, Australia August 2008. Poster
- Ouvrages et Proceedings – Works and proceedings**
1. Living donor transplantation. Surgical complications. G. Karam. **Néphrologie et Thérapeutique**. 2008, 4 : 69-71.
 2. Néogenèse lymphoïde au cours du rejet chronique: une réponse humorale alloimmune locale. O Thauinat, N Patey, C Gautreau, E Morelon, JB Michel, A Nicoletti. **Actualités néphrologiques Jean Hamburger-Hôpital Necker** 2008 (p113-120). Editions Flammarion Médecine Sciences.
 3. Coordination du chapitre « Transplantation rénale ». Les essais thérapeutiques en néphrologie : du concept à la pratique. Emmanuel Morelon. Volume 2. Editions Vivactis medical Education.

R4- Liste des invitations pour séminaires internationaux - *List of international invited conferences*

1. Les outils de la pharmacologie. S. Brouard (*Invited speaker*). **9^e Colloque de la Section 30 du CNRS « De la Recherche à la Découverte »**, Université de Nice Sophia Antipolis, Parc Valrose, France, January 8-9th 2008.
2. Predicting Immunologic risk following transplantation. J.P. Souillou (*Invited speaker*). **TTS New Key Opinion Leader Meeting**, Costa Rica, January 17-20th 2008.
3. Predicting Immunologic risk following transplantation. S. Brouard (*Invited speaker*). **TTS New Key Opinion Leader Meeting**, Costa Rica, January 17-20th 2008.
4. State of the art: Tolerance: When can we stop immunosuppression? J.P. Souillou (*Invited speaker*). **Meeting of Swiss Society of Transplantation**, Geneva, Switzerland, January 25-26th, 2008.
5. Mécanisme et signature moléculaire de la tolérance opérationnelle en transplantation rénale. S.Brouard (*Invited speaker*). **La recherche en transplantation, actualités et perspectives**, Institut de France, Paris, France, February 12th 2008.
6. Conclusions et perspectives de la réunion. J.P. Souillou (*Invited speaker*). **Colloque Fondation Greffe de Vie**, Paris, France, February 12th, 2008.
7. Xénotransplantation, quels enjeux, quels espoirs ? G. Blancho (*Invited speaker*). **Séminaires d'Uro-Néphrologie de la Pitié Salpêtrière**, Paris, France, 2008.
8. Le parcours du futur chercheur en Neurosciences. L. Lescaudron (*Invited speaker*). **Semaine du Cerveau**, Faculté de Médecine de Nantes, Nantes, France, March 11th 2008.
9. Interview radio par EURONANTES dans le cadre de la **Semaine du Cerveau**. L. Lescaudron (*Invited speaker*). March 13th 2008.
10. Interview radio par EURONANTES la recherche effectuée en Neurosciences à l'INSERM U643 : Maladies de Parkinson et de Huntington, allo- et xéno greffe de cellules souches. L. Lescaudron (*Invited speaker*). March 13th 2008.
11. Perspectives thérapeutiques dans la maladie de Parkinson. P. Damier (*Invited speaker*). **Semaine du cerveau**, Grenoble, France, March 13th 2008.
12. Tolerogenic DCs induced by heme oxygenase-1, I.Anegon (*Invited speaker*). **Seminar, Departamento de Immunologia**, Universidad Catolica, Santiago de Chile, Chile, March 14th 2008.
13. Deep brain stimulation for Parkinson's disease. P. Damier (*Invited speaker*). **First French-Chinese meeting on Translational research**, Canton, Chine, March 17th 2008.
14. La maladie neurodégénérative de Huntington : du gène au déficit comportemental. L. Lescaudron (*Invited speaker*). **Rotary de Pornic/Pays de Retz**, La Bernerie en Retz, France, March 25th 2008.
15. Rôle des noyaux gris centraux dans le contrôle de la marche. P. Damier (*Invited speaker*). **Colloque « Mouvement et Risque »**, Royaumont, France, March 29th 2008.
16. Approche sémiologique des accidents vasculaires cérébraux. P. Damier (*Invited speaker*). **Congrès de gériatrie de l'Ouest**, La Baule, France, May 30th 2008.
17. How biomarkers "see" a population of stable long-term kidney recipients: a basis for immunosuppressive weaning. **Symposium ROTRF « Presented for attendees of the American Transplant Congress »**. J.P. Souillou (*Invited speaker*), Toronto, Canada, May 30th, 2008.
18. **Congrès National des Etablissements de Dialyse**. J.P. Souillou (*Invited speaker*). Nantes, France, June 6th 2008.
19. Un rôle original de la molécule immunitaire CD3zeta dans le développement neuronal. H. Boudin (*Invited speaker*). **IFR des Neurosciences**, Institut Jean Roche, Marseille, France, June 9th 2008.
20. Can blood biomarkers help to understand the barriers to immunological tolerance in mens? S. Brouard (*Invited speaker*). **8e rencontres de Beaune**, Beaune, France, June 12-13 2008.
21. Tolerance strategies in gene therapy. I. Anegon (*Invited speaker*). Invited speaker and round table for **the annual meeting of the American Society for Gene Therapy (ASGT)**, Boston, USA, June 2008.
22. Lentiviral transgenesis, I. Anegon (*Invited speaker*). **Lentiviral vectors, advanced course**, University of Evry and Genethon, France, June 29-July 5th 2008.
23. CD8+ T regulatory cells in an allotransplantation model. I. Anegon (*Invited speaker*). **Seminar, University of Melbourne**, Australia, laboratory of P. Doherty, August 14th 2008.
24. Patient needs and treatment options in Parkinson's disease. P. Damier (*Invited speaker*). **Annual Congress of the European Federation of Neurological Societies**, Madrid, Spain, August 25th 2008.
25. Biomarkers of Operational Tolerance. J.Ashton-Chess (*Invited speaker*). **8th International Congress of Lung Transplantation**, Paris, France, September 11-12nd 2008.
26. Blood biomarkers of spontaneous tolerance to human mismatch kidney allografts. J.P. Souillou (*Invited speaker*). **Franco-Israeli workshop on Regulatory T-cells, Tolerance, Transplantation and Immunotherapy**, Jerusalem, Israël, September 14-15th 2008.
27. Axon differentiation mediated by CXCR4. H.Boudin (*Invited speaker*). **Gordon Research Conferences, Chemotactic Cytokines**, Aussois, France, September 21-26th 2008.
28. Nouvelles frontières sémiologiques dans la maladie de Parkinson. P. Damier (*Invited speaker*). **Colloque annuel des neurologues hospitaliers de la région Rhône-Alpes**, Macon, France, October 18th 2008.
29. **Aspects immunologiques des infections virales**. G. Blancho (*Invited speaker*). Echanges cliniques en transplantation, Marseille, France, November 5th 2008.
30. The operational tolerance, J.P. Souillou (*Invited speaker*). **Hesperis Teaching Course**, Nogent/Marne, France, November 4-9th 2008.
31. Les indications du traitement par neurostimulation dans la maladie de Parkinson. P. Damier (*Invited speaker*). **Congrès Annuel de Neurologie des pays du Maghreb**, Alger, November 7th 2008.
32. Gestion des fluctuations d'efficacité du traitement de la maladie de Parkinson. P. Damier (*Invited speaker*). **Congrès Annuel de Neurologie des pays du Maghreb**, Alger, Algeria, November 7th 2008.
33. The modifying-disease effect of Rasagiline in Parkinson's disease. P. Damier (*Invited speaker*). Athènes, Greece, November 8th 2008.
34. The modifying-disease effect of Rasagiline in Parkinson's disease. P. Damier (*Invited speaker*). Thessalonique, Greece, November 8th 2008.
35. Innate immunity in transplantation: important role of the complement. **Symposium satellite of the Network Complement Related Diseases: Trends in innate immunity**. G. Blancho (*Invited speaker*). Bangkok, Thailand, November 12-15th 2008.
36. Options thérapeutiques basées sur des preuves dans la maladie de Parkinson. P. Damier (*Invited speaker*). **Journées de neurologie du Saumurois**, Saumur, France, November 15th 2008.
37. Global consultation on Regulatory Requirements for xenotransplantation Clinical Trials. G. Blancho (*Invited speaker*). **World Health Organization**, Changsha, China, November 19-21st 2008.
38. Dominique Chabannes (*Invited speaker*). **MISOT 2008**. Regensburg, Germany, November 24th 2008.
39. Gene therapy in transplantation. I. Anegon (*Invited speaker*). **Plenary session of Middle East Society for Organ Transplantation (MESOT)**, Shiraz, Iran, November 2008.
40. Lentiviral transgenesis. I. Anegon (*Invited speaker*). **International course "Genetics of laboratory rodents" EMBO practical course**, Instituto Pasteur de Montevideo, Uruguay, November 24-December 5th 2008.

41. Immunomodulation with CD28 antagonists. Biologics in Transplantation. B. Vanhove (*Invited speaker*). **American Society of Transplantation**, Miami Beach, USA, December 5-6th 2008.
42. Therapeutical guidelines in the humoral rejection. J.P. Souillou (*Invited speaker*). **40th course on advances in nephrology and dialysis**, Milan, Italy, December 5-8th 2008.
43. The need for tolerance induction after face transplantation. E. Morelon. **Congrès annuel de la SFH-2nd European ECP meeting** - Paris, France 2008.
44. Cancers sous immunosuppression. E. Morelon. **Symposium de transplantation d'organe et de tissus**. La Pitié Salpêtrière - Paris, France 2008.
45. Retransplantation rénale préemptive. E. Morelon. **Atelier Francophone de Transplantation** - Dubrovnik, Croatia, 2008.
46. Prélèvements à cœur arrêté à Lyon. Résultats à un an. E. Morelon. **Congrès de l'AFIDTN** - Lyon, France 2008.
47. Principe de précaution et immunosuppression. E. Morelon. **Congrès annuel du GAM**. Paris, France, April 2008.
48. Athérosclérose et inflammation: le modèle du rejet vasculaire chronique. O. Thauat. (*Invited speaker*) **4th Symposium lipides et athérosclérose**, Brussels, Belgium, September 2008.
49. Local humoral allogenic response in chronic rejection. O. Thauat (*Invited speaker*). **8th International Congress on Lung Transplantation**, Paris, France, September 2008.
50. Lymphoid neogenesis during chronic rejection: evidence for a local alloimmune response. O. Thauat (*Invited speaker*). **ULB-Institute for Medical Immunology**. Brussels, Belgium, June 2008.
51. Lymphoid neogenesis: a therapeutic target for chronic rejection? O. Thauat (*Invited speaker*). **Taipei International Organ Transplantation Forum**. Taipei, Chine, April 2008.
52. Néogenèse lymphoïde au cours du rejet chronique : une réponse humorale alloimmune locale. O. Thauat (*Invited speaker*). **Actualités néphrologiques Jean Hamburger**, Paris, France, April 2008.
53. Réponse alloimmune humorale locale au cours du rejet chronique. O. Thauat (*Invited speaker*). **Académie des Sciences**, Paris, France, February 2008.
54. Harvard Medical School. JM Dubernard (*Invited lecture+visiting Professor*). **1st Joe Murray lecture**. Boston, USA March, 5 -7th 2008.
55. JM. Dubernard (*Invited lecture*). **Scandinavian Microsurgical Society**. Fyn, Denmark April 3rd 2008.
56. JM Dubernard (*Invited lecture*). **Congrès du Groupe pour l'avancement de la microchirurgie**. Paris, France, April 19th 2008.
57. Debate on "identity". JM Dubernard. **Cultural Chamonix Festival**. Chamonix, France, May 1st 2008.
58. JM. Dubernard (*Invited lecture + visiting Professor*). **John Najarian. Lecture**. University of Minnesota. Minneapolis, USA May 5th 2008.
59. JM Dubernard (*Invited lecture*). **Emory University dpt. of plastic and hand surgery**. Atlanta, USA, May 7th 2008.
60. JM. Dubernard (*Invited lecture*). **American Society for Reconstructive Surgery**. Philadelphia, USA July 17th 2008.
61. Medawar prize acceptance speech. JM. Dubernard. **XXII International Congress of the Transplantation Society**. Sydney, Australia August, 10th 2008.
62. JM Dubernard (*Invited lecture*). **9^e journée de cyber FMC@chu de Nice**. Nice, France, September 5th 2008.
63. JM. Dubernard (*Invited lecture*). **European Society for Pediatric Nephrology**. Lyon, France, September 11th 2008.
64. JM Dubernard (*Invited lecture*). **Journée de l'école doctorale "Biologie et Santé"** Lille, France, September 18th 2008.
65. JM Dubernard (*Invited lecture*). **Third Nordic Transplant Fellow Workshop**. Gothenburg, Sweden, September 27th 2008.
66. JM Dubernard (*Invited lecture*). **The New Yorker Festival. Conversation** with Atul Gawande "about face and identity". New York, USA, October 4th 2008.
67. JM Dubernard (*Invited lecture*). **Research Day at Herlev Hospital**. Copenhagen, Denmark, October 23rd 2008.
68. « Les donneurs limites». C. Legendre. (*Invited lecture*) **SRLF**. January 2008.
69. Les patients à haut risque immunologique. C. Legendre. (*Invited lecture*) **Séminaires UN de la Pitié Salpêtrière**. Paris, France January 22nd 2008.
70. Les patients à haut risque immunologique. C. Legendre. (*Invited lecture*) **Académie des Sciences**. February 12th 2008.
71. La greffe avec donneur vivant. C. Legendre. (*Invited lecture*) **Réunion des Néphrologues du Sud Ouest** ; February 14th 2008.
72. **Groupe de Venise** : La biopsie de routine en transplantation rénale. C. Legendre. (*Invited lecture*) May 16th 2008.
73. Exposing the myth of the stable patient. C. Legendre. (*Invited lecture*) **Protecting the graft Meeting**. Frankfurt, Germany, September 26th 2008.
74. La néphrotoxicité des immunosuppresseurs. C. Legendre. (*Invited lecture*) **Société Française de Transplantation**. October 8th 2008.
75. Symposium Roche. Prophylaxie du CMV en transplantation rénale. C. Legendre. (*Invited lecture*) **Société Française de Transplantation**. October 9th 2008.
76. Symposium Novartis Actualités sur les inhibiteurs de mTOR. C. Legendre. (*Invited lecture*) **Société Française de Transplantation**. October 10th 2008.
77. De l'observation clinique à l'évaluation des pratiques : Les nouveaux visages du rejet en 2008. C. Legendre (*Invited lecture*) Nancy, France October 16th 2008.
78. SN Echanges cliniques Novartis Greffon limite et bigreffe. C. Legendre. (*Invited lecture*) Marakech, Morocco, November 26th 2008.
79. Education on organ donation and transplantation in schools. F. Cantarovich, M. Cantarovich, L. Falco, R. Revello, C. Legendre, A.Herrera-Gayol. **XIII International Congress of the Transplantation Society**. Sidney, Australia August 2008.
80. CD3 Monoclonal Antibodies to promote clinical immune tolerance. L. Chatenoud (*Invited lecture*) **8th International Conference on New Trends on Immunosuppression and Immunotherapy**. Berlin, Germany. February 2008
81. Induction de la Tolérance L. Chatenoud (*Invited lecture*) **Colloque sur la recherche en Transplantation**. Institut de France, Paris, France. February 2008
82. Adaptive regulatory T cells in the control of autoimmunity: a privileged target for immunotherapy. L. Chatenoud (*Invited lecture*) **Joint Symposium INSERM-RIKEN/RCAI - Pasteur Institute**. Domaine des Vaux de Cernay, Auffargis, France. March 2008
83. Traitements immunomodulateurs dans le diabète de type 1 - L. Chatenoud (*Invited lecture*) **ALFEDIAM (Congrès Francophone Annuel de Diabétologie)**. Bruxelles, Belgium. March 2008
84. Emerging therapeutic approaches to preserve beta cell function in type 1 diabetes. L. Chatenoud (*Invited lecture*) **10th European Congress of Endocrinology**. Berlin, Germany. May 2008
85. Traitement par anti-CD3 et T régulateurs. L. Chatenoud (*Invited lecture*) **7^{ème} journée scientifique du CRI (Club Rhumatisme et Inflammation (CRI))**. Institut Pasteur, Paris, France. Mai 2008
86. Immunomodulatory treatment of type 1 diabetes. L. Chatenoud (*Invited lecture*) **50^o congreso de la sociedad espanola de Endocrinologia y nutricion (SEEN)**, Bilbao, Spain. May, 2008
87. Immunoregulatory therapy. L. Chatenoud (*Invited lecture*) **5th world congress on prevention of diabetes and its complications (WCPD)**, Helsinki, Finland. June, 2008

88. Immunothérapie du diabète de type 1. L. Chatenoud (*Invited lecture*). **Journées de Médecine et de Biologie France - Argentine**, Paris, France. Juin 2008
89. CD3-specific antibodies: a step towards clinical immune tolerance. S. You (*Invited lecture*) **French-Israeli workshop on regulatory T cells, tolerance and immunotherapy**. Jerusalem, Israel 2008
90. Anti-T cell monoclonal antibodies as privileged tools to promote immune tolerance in clinical organ transplantation. S. Candon (*Invited lecture*) **4th International Conference: Living Donor Abdominal Organ Transplantation: State of the Art**, Sorrento, Italy, June 20-21, 2008.
91. Mécanismes du rejet en transplantation - L. Chatenoud (*Invited lecture*). **63èmes journées de l'AFEF (Association Française pour l'Etude du Foie)**, Paris, France. September 2008
92. Restoration of self-tolerance in overt autoimmunity: the use of CD3-specific monoclonal antibodies. L. Chatenoud (*Invited lecture*). **Annual Congress of the British Society of Immunology (BSI)**, Glasgow, United Kingdom, UK - November 2008

R5-Thèses (et/ou master) encadrés - *Thesis (and/or masters) supervised*

- | | |
|---|---|
| ▶ 21 janvier 2008 Annabelle CHAUVEAU - Spécialité : Immunologie | <i>January 21, 2008 Annabelle CHAUVEAU - Focus on immunology</i> |
| ▶ 19 mai 2008 Caroline BALLET - Spécialité : Immunologie | <i>May 19, 2008 Caroline BALLET - Focus on immunology</i> |
| ▶ 17 juin 2008 Anne-Sophie DUGAST - Spécialité : Immunologie | <i>June 17, 2008 Anne-Sophie DUGAST - Focus on immunology</i> |
| ▶ 23 juin 2008 Fanny BURON - Spécialité : Immunologie | <i>June 23, 2008 Fanny BURON - Focus on immunology</i> |
| ▶ 7 juillet 2008 Aurélié MOREAU - Spécialité : Immunologie-Virologie | <i>July 7, 2008 Aurélié MOREAU - Focus on immunology-virology</i> |
| ▶ 25 septembre 2008 Vincent HENRY - Spécialité : Neuroimmunologie | <i>September 25, 2008 Vincent HENRY - Focus on neuroimmunology</i> |
| ▶ 30 septembre 2008 Albane SARTORIUS - Spécialité Néphrologie | <i>September 30, 2008 Albane SARTORIUS - Focus on nephrology</i> |
| ▶ 1 ^{er} octobre 2008 Thibaut QUILLARD - Spécialité : Immunologie | <i>October 1st 2008 Thibaut QUILLARD - Focus on immunology</i> |
| ▶ 16 décembre 2008 Chantal KUHN - Spécialité : Immunologie | <i>December 16, 2008 Chantal KUHN - Focus on immunology</i> |

R6- Les brevets déposés - *Registered patents*

- ▶ Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease. Patent N° 07290545.8-2406, date: 19.05.08 date of filing: 30.04.07
Inventeurs: F. Triebel, B. Vanhove, T. Haudebourg.
- ▶ Biomarkers for the diagnosis of renal allograft and kidney status. EP 08305988 date : 19 décembre 2008
Inventeurs : Sandrine Le Roux, Maryvonne Hourmant et Jean Harb

R7- Les chercheurs et cliniciens étrangers accueillis - *Welcomed foreign researchers and clinicians*

- ▶ Léandro CARRENO : stagiaire Chilien - *Chilean Student*

R8- Programmes de recherche financés - *Financed research programs*

- ▶ **ANR 05 - OSEO ANVAR ANR05PRIB02002 - S0602068W** (*Projet APIC 28* "Accroissement des propriétés pharmacodynamiques d'un immunosuppresseur ciblant sélectivement CD28")
- ▶ **ANR n° ANR-05-PNRA-004-09** (Détection des nutriments et contrôle de la prise alimentaire : Impact des déséquilibres nutritionnels /NUTRISENS)
- ▶ **ANR-06-RIB-010-02** "ImmuTune, a research program on two LAG-3 specific mAbs /IMMUTEP" OSEO ANVAR Programme GIP ANR-06 RIB
- ▶ **FRM** (lauréate du Prix Victor et Erminia MESCLE 2007) : "Déterminer le rôle de CLEC-1n un récepteur lectin de type C-dans la tolérance immune"
- ▶ **DHOS/INSERM/InCA (AO 2008)** "Validation de marqueurs phénotypiques et transcriptionnels du rejet chronique dans une étude prospective un an après transplantation"
- ▶ **PHRC** "Evaluation d'un test de dépistage précoce (par puces ADN) du rejet chronique et de l'état de tolérance opérationnelle en transplantation rénale"
- ▶ **PHRC** "Dépistage sur puce oligonucléotidique panvirale de virus émergents chez le sujet immunosupprimé après transplantation rénale ou pancréatique"
- ▶ **PHRC National** « Evaluation de l'intérêt de la machine de perfusion dans la préservation des greffons rénaux issus de donneurs marginaux : étude IMPULSION »
- ▶ **ANR** "Appel 2006 PHYSIO - EMPRSNICR"
- ▶ **ANR - Appel à projets 2007 JCJC** "Deciphering the role of Tribbles Homolog 1, a novel biomarker in transplantation" n° JC07_211446
- ▶ **DHOS/INSERM (AP 2007)** "Etude des anticorps auto-immuns et anti-HLA présents dans le rejet chronique en transplantation rénale"
- ▶ **DHOS/INSERM/InCA (AO 2008)** "Validation de marqueurs phénotypiques et transcriptionnels du rejet chronique dans une étude prospective un an après transplantation"
- ▶ **ROTRF CI: 705613444** "Study of CMV/DC interplays in human renal allograft transplantation"
- ▶ **ROTRF CI: 770012174** "Characterization of TORID, a new member of the CD20/FcεR1B family, overexpressed in a model of allograft tolerance"
- ▶ **ROTRF CI: 415394615** "The role of plasmacytoid dendritic cells in the expansion and function of CD4+CD25+ regulatory T cells"
- ▶ **ROTRF CI: 936864657** "Heme oxygenase-1 promotes tolerogenic dendritic cells: analysis of mechanisms and in vivo applications"
- ▶ **ROTRF CI: 466230972** "*Immunosuppression and tolerance induction by selective inhibition of CD28*"
- ▶ **AFM - AO2007** "Advantage of cografing in neurorestaurative strategies" n° 13064 - Projet : Fonctions immunomodulatrices des MSC en xénotransplantation neurale"

R9- Réseaux européens - *European networks*

Promoteur	N° Contrat	Intitulé	Inv. Principal	Inv. local	date début	date fin
CEE	LSHB-CT-2005 n° 512090IP	<i>"Reprogramming the immune System for the Establishment of Tolerance. "RISET"</i>	Université Libre de Bruxelles (Michel Goldman)	J.P. Soullillou/ M.C. Cuturi	01/03/2005	28/02/2010
CEE	EU/FP6	<i>Associate Member, Réseau d'Excellence DC-THERA (Dendritic cells and novel immunotherapy), EU/FP6 / R. JOSIEN et M.C. CUTURI</i>				
CEE	LSHB-CT-2006-032732	<i>XENOME "Engineering of the porcine genome for xenotransplantation studies in primates: a step towards clinical application"</i>	Azienda Ospedaliera di Padova (Italie) (Emanuele Cozzi)	G. Blanco/ B. Charreau/ P. Naveilhan	01/11/2006	31/10/2011
CEE	LSHB-CT-2005 n° 512090IP	<i>"Reprogramming the immune System for the Establishment of Tolerance. "RISET"</i>	Université Libre de Bruxelles (Michel Goldman)	L. Chatenoud	01/03/2005	28/02/2010

R10- Prix décernés aux membres du réseau - *Awarded prizes to members of the network*

- ▶ **Sophie Brouard** : Prix de la Fondation Jean Varade, sous l'égide de la Fondation de France.
- ▶ **Lucienne Chatenoud** : Prix Lecoq de l'Académie des Sciences (Paris, France, Novembre 2008)
- ▶ **Jean-Michel Dubernard** : Prix Medawar (Sidney, Australie, août 2008)
- ▶ **Jean-Paul Soullillou** : the 2008 Transplantation Society Award for " Outstanding Achievement in Transplantation Science" (BASIC)